Comment from McKesson Corporation

Summary: McKesson Corporation supports the FDA's initiative to explore AI-enabled optimization of early-phase clinical trials and commends the agency's focus on addressing bottlenecks in the research ecosystem. The company recommends a risk-based governance framework, a focus on data quality, and the inclusion of operational feasibility and equity metrics in the pilot's evaluation.